Market closed

Rani Therapeutics/$RANI

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Rani Therapeutics

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.

Ticker

$RANI

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

San Jose, United States

Employees

140

Website

www.ranitherapeutics.com

RANI Metrics

BasicAdvanced

$43M

-

-$1.05

0.11 -

Price and volume

Market cap

$43M

Beta

0.11

52-week high

$8.75

52-week low

$1.24

Average daily volume

488K

Financial strength

Current ratio

1.602

Quick ratio

1.504

Long term debt to equity

303.965

Total debt to equity

584.104

Interest coverage (TTM)

-9.95%

Management effectiveness

Return on assets (TTM)

-56.80%

Return on equity (TTM)

-270.57%

Valuation

Price to book

12.23

Price to tangible book (TTM)

12.23

Price to free cash flow (TTM)

-0.863

Growth

Earnings per share change (TTM)

-25.45%

3-year earnings per share growth (CAGR)

87.59%

What the Analysts think about RANI

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Rani Therapeutics stock.

RANI Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

RANI Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RANI

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Rani Therapeutics stock?

Rani Therapeutics (RANI) has a market cap of $43M as of January 15, 2025.

What is the P/E ratio for Rani Therapeutics stock?

The price to earnings (P/E) ratio for Rani Therapeutics (RANI) stock is 0 as of January 15, 2025.

Does Rani Therapeutics stock pay dividends?

No, Rani Therapeutics (RANI) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Rani Therapeutics dividend payment date?

Rani Therapeutics (RANI) stock does not pay dividends to its shareholders.

What is the beta indicator for Rani Therapeutics?

Rani Therapeutics (RANI) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.